DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes
Open Access
- 22 January 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1), e0245667
- https://doi.org/10.1371/journal.pone.0245667
Abstract
Large inter-individual variations in drug metabolism pose a challenge in determining 6-mercaptopurine (6MP) doses. As the last product of 6MP metabolism, DNA-thioguanine nucleotide (DNA-TGN) could reflect the efficacy of 6MP, especially in patients harboring variants in the 6MP metabolism pathway. The aim of this study was to investigate the clinical significance of DNA-TGN monitoring in Korean pediatric acute lymphoblastic leukemia (ALL) patients, focusing on the NUDT15 genotype. The subjects of this study were patients who underwent ALL treatment with 6MP. Tests for the NUDT15 and TPMT genotypes were performed, and prospective DNA-TGN and erythrocyte TGN samples were collected after two weeks or more of 6MP treatment. DNA-TGN was quantified using the liquid chromatography-tandem mass spectrometry method. A total of 471 DNA-TGN measurements in 71 patients were analyzed, which ranged from 1.0 to 903.1 fmol thioguanine/μg DNA. The 6MP intensity demonstrated a significant relationship with DNA-TGN concentration (PNUDT15 variants were treated with a lower dose of 6MP (PNUDT15 (P = 0.261). These patients also presented higher variation in DNA-TGN levels (P = 0.002) and DNA-TGN/6MP intensity (P = 0.019) compared to patients carrying wild-type NUDT15. DNA-TGN concentration did not show a significant correlation with WBC count (P = 0.093). Patients harboring NUDT15 variants demonstrated similar DNA-TGN concentrations even at low doses of 6MP and showed high variability in DNA-TGN. Particularly in patients with NUDT15 variants who need a reduced 6MP dose, DNA-TGN could be applied as a useful marker to monitor the therapeutic effect of 6MP.Funding Information
- Korean Foundation for Cancer Research (KFCR-2017-D-1)
This publication has 24 references indexed in Scilit:
- DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trialThe Lancet Oncology, 2017
- Maintenance therapy of childhood acute lymphoblastic leukemia revisited—Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?Pediatric Blood & Cancer, 2016
- NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemiaThe Pharmacogenomics Journal, 2015
- Inherited genetic variation in childhood acute lymphoblastic leukemiaBlood, 2015
- Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic LeukemiaJAMA Oncology, 2015
- Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2015
- Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2014
- A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopeniaNature Genetics, 2014
- Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 studyLeukemia, 2008
- Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancerNature Reviews Cancer, 2008